« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 120, Issue 3 , Pages 594-601 , September 2007

Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

Shabnam Foroughi, MD
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Barbara Foster, MS
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
NaYoung Kim, MD
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Leigh B. Bernardino, RN
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Linda M. Scott, CRNP
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Robert G. Hamilton, PhD
- Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md
Dean D. Metcalfe, MD
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Peter J. Mannon, MD
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
Calman Prussin, MD
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
- Reprint requests: Calman Prussin, MD, Building 10, Room 11C205, NIH, Bethesda, MD 20892-1881.

Received 26 January 2007 ,Revised 6 June 2007 ,Accepted 7 June 2007.

Effect of omalizumab on peripheral blood eosinophil counts. Peripheral blood AECs were determined at baseline (week 0) and every 2 weeks thereafter for the duration of the study. The actual values for

Effect of omalizumab on peripheral blood eosinophil counts. Peripheral blood AECs were determined at baseline (week 0) and every 2 weeks thereafter for the duration of the study. The actual values for each time point (A), as well as the value as a percentage of the preomalizumab baseline (B), are shown.
- Full-Size Image
- Download to PowerPoint
Effect of omalizumab on tissue eosinophil counts. Esophagogastroduodenoscopy was performed at baseline and again after 16 weeks of omalizumab therapy, and the median number of eosinophils per hpf in t

Effect of omalizumab on tissue eosinophil counts. Esophagogastroduodenoscopy was performed at baseline and again after 16 weeks of omalizumab therapy, and the median number of eosinophils per hpf in the duodenum (A), gastric antrum (B) and body (C), and esophagus (D) were determined. Data are shown as the median value for each subject.
- Full-Size Image
- Download to PowerPoint
Efficacy of omalizumab in blocking IgE. Changes in the levels of serum free IgE (A), basophil-associated IgE (B), FcɛRI expression by peripheral blood basophils (C), myeloid DCs (mDC; D), and pDCs (E)

Efficacy of omalizumab in blocking IgE. Changes in the levels of serum free IgE (A), basophil-associated IgE (B), FcɛRI expression by peripheral blood basophils (C), myeloid DCs (mDC; D), and pDCs (E) are shown. The above were determined at baseline and again after 16 weeks of omalizumab. Free IgE was determined at baseline and serially thereafter. ^∗P < .005 for each time point relative to baseline. Fluorescence intensity was quantitated as molecules of equivalent phycoerythrin (MEPE).
- Full-Size Image
- Download to PowerPoint
Efficacy of omalizumab in blocking basophil activation. Basophil CD63 expression after in vitro activation by anti-IgE (A) and allergen (data not shown) was measured, and the EC50 was calculated for e

Efficacy of omalizumab in blocking basophil activation. Basophil CD63 expression after in vitro activation by anti-IgE (A) and allergen (data not shown) was measured, and the EC₅₀ was calculated for each, respectively (B and C). D and E, Constitutive basophil CD63 expression without or with added IL-3. F, Basophil CD63 expression after N-formyl-methionine-leucine-phenylalanine activation. The results were determined at baseline and again after 16 weeks of omalizumab.
- Full-Size Image
- Download to PowerPoint
Efficacy of omalizumab in blocking immediate hypersensitivity. Wheal (A) and erythema (B) after food and aeroallergen titration skin testing at baseline and after 16 weeks of omalizumab. Each result i

Efficacy of omalizumab in blocking immediate hypersensitivity. Wheal (A) and erythema (B) after food and aeroallergen titration skin testing at baseline and after 16 weeks of omalizumab. Each result is the mean of 2 skin tests.
- Full-Size Image
- Download to PowerPoint
Effect of omalizumab on EGID symptom scores. A, EGID symptom scores at baseline, midstudy (weeks 7-8), and end of study (weeks 15-16). B, EGID symptom scores were calculated as a percentage of the bas

Effect of omalizumab on EGID symptom scores. A, EGID symptom scores at baseline, midstudy (weeks 7-8), and end of study (weeks 15-16). B, EGID symptom scores were calculated as a percentage of the baseline value for each subject. ^∗P < .005 for each time point relative to baseline.
- Full-Size Image
- Download to PowerPoint